MedTrace Logo

Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis

NCT02022930 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 510

Last updated 2016-08-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of Hydros-TA Joint Therapy for relief of pain due to OA of the knee. Hydros-TA is designed to provide fast acting and long lasting pain relief for up to six months with a single IA injection.

Conditions

  • Osteoarthritis of the Knee

Interventions

DEVICE

Hydros

DEVICE

Hydros-TA

DRUG

Triamcinolone Acetonide

Sponsors & Collaborators

  • Carbylan Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-12-31
Completion
2016-06-30

Countries

  • Australia
  • Canada
  • Netherlands Antilles

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02022930 on ClinicalTrials.gov